热门资讯> 正文
艾伯维启动耗资7000万美元的研发建设和制造中心扩建
2025-10-01 04:44
- AbbVie (NYSE:ABBV) has broken ground on a $70M expansion of an existing site in Worcester, Mass., that serves as a biologics R&D center and manufacturing facility.
- The company said the additional space will boost its biologics manufacturing capacity. The plan also calls for a three-story building for laboratory, warehouse, and office space. Also, the new facilities will speed up the transfer of some oncology therapies from Europe to the U.S.
- During its Q1 earnings call in late April, AbbVie management said it would invest $10B to improve its supply chain in the US.
More on AbbVie
- AbbVie For Healthy Dividend Growth
- AbbVie: Best Time To Sell In 5 Years (Rating Downgrade)
- AbbVie Inc. (ABBV) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
- AbbVie launching ovarian cancer therapy Elahere in UK at US list price
- SA analyst upgrades/downgrades: AMD, SNOW, MU, and ABBV
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
